Zevra Therapeutics, Inc.

The momentum for this stock is not very good. Zevra Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Zevra Therapeutics, Inc. .

News

William Blair Keeps Their Buy Rating on Zevra Therapeutics (ZVRA)

TipRanks Financial Blog William Blair analyst Sami Corwin reiterated a Buy rating on Zevra Therapeutics (ZVRA - Research Report) today. The company's shares opened today a...\n more…

Zevra Therapeutics presents data for arimoclomol, OLPRUVA at SSIEM 2024

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Globe Newswire New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful...\n more…

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Simply Wall St Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 34% gain in the last month...\n more…

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Globe Newswire CELEBRATION, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane...\n more…

Price T Rowe Associates Inc. MD Makes New $64,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zolmax Price T Rowe Associates Inc. MD bought a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities...\n more…